CEOINSIDER
Xlife Sciences AG logo

Company

Xlife Sciences AG

Public · Swiss Stock Exchange: XLSSwitzerland

Xlife Sciences AG is a Swiss life sciences investment holding company that develops and commercializes early-stage research from universities and research institutions into healthcare solutions. The company operates across four segments: technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health. It supports portfolio companies from inception through proof-of-concept before facilitating exits through sales or licensing.

Xlife Sciences AG is a publicly traded company, based in Switzerland. It trades on the Swiss Stock Exchange under the ticker XLS. Leadership tracked by CEOInsider includes Oliver R. Baumann (CEO).

www.xlifesciences.ch ↗LinkedIn ↗

Leadership

Current

Recent developments

AI summary of recent coverage

Recent coverage has focused on Xlife Sciences AG's portfolio activities, including the exit of multiple project companies to Grupo Landsteiner and the public debut of VERAXA Biotech, a cancer therapy company within its ecosystem. The company has pursued listing on Swiss exchange platforms to support its investment and development strategy.

Summarized from the headlines in the sidebar; see each source for the full story.